(Bloomberg Stock Exchange & Finance: page 43, Repubblica Affari & Finanza: page 14 – 8 October 2007)
With the acquisition of Orphan Europe, Recordati opens up to the American market. The acquisition is strategically important because it will accelerate growth while maintaining the good level of profitability. Specialized in the development of drugs for rare diseases, Orphan Europe has a geographically well-distributed turnover and a well-established presence in the USA, where Recordati is not active. This will represent the opportunity to launch own products in an area not currently covered. For the share of the Italian company, today at its all-time high around 6.80 euros, analysts support a bullish hypothesis, with a target of 8 euros.
http://www.aboutpharma.it/notizia.asp?id=14493
Shire sells assets for €151m
(Les Echos online – October 8, 2007)
Shire has announced that it has sold a portfolio of non-strategic products, mainly in the dermatology sector, to the Spanish company Almirall. The operation has a value of 151 million euro.
http://www.aboutpharma.it/notizia.asp?id=14491
"No thrills and a lot of security with Nestlé, Novartis and Roche"
(CorrierEconomia: page 19 – 8 October 2007)
The Swiss market is placed by the managers in 4th place among the major European stock exchanges. Among the strengths is the massive presence of companies that belong to the defensive sectors par excellence: pharmaceuticals (Novartis and Roche) and food (Nestlé). Investors' fortunes are at stake precisely on Roche and Novartis, whose capitalization exceeds the 25% of the Zurich stock exchange.
http://www.aboutpharma.it/notizia.asp?id=14501
"First yes to simplification"
(Il Sole 24 Ore: page 33 – 8 October 2007)
The bill for the 'simplification of obligations for the protection of health' was approved on Wednesday 3 October by the Senate's Hygiene and Health Commission. There are many consequences, including: the abolition of about 5 million certificates, from the 'healthy and robust constitution' to the vaccination certificate necessary for enrollment in the 1st year of primary school; guarantee of a fast track for 'severe' pain medications, for which an ordinary prescription from the NHS will suffice, and no longer that
